Neurocrine Biosciences (Brazil) Performance
| N1BI34 Stock | 36.16 0.49 1.37% |
The company secures a Beta (Market Risk) of 0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Neurocrine Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neurocrine Biosciences is expected to be smaller as well. At this point, Neurocrine Biosciences has a negative expected return of -0.19%. Please make sure to verify Neurocrine Biosciences' kurtosis, rate of daily change, and the relationship between the skewness and daily balance of power , to decide if Neurocrine Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's fundamental drivers remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 190.3 M | |
| Total Cashflows From Investing Activities | -130.2 M |
Neurocrine |
Neurocrine Biosciences Relative Risk vs. Return Landscape
If you would invest 4,194 in Neurocrine Biosciences on August 27, 2024 and sell it today you would lose (578.00) from holding Neurocrine Biosciences or give up 13.78% of portfolio value over 90 days. Neurocrine Biosciences is generating negative expected returns and assumes 2.8902% volatility on return distribution over the 90 days horizon. Simply put, 25% of stocks are less volatile than Neurocrine, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Neurocrine Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurocrine Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurocrine Biosciences, and traders can use it to determine the average amount a Neurocrine Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0662
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | N1BI34 |
Estimated Market Risk
| 2.89 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neurocrine Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurocrine Biosciences by adding Neurocrine Biosciences to a well-diversified portfolio.
Neurocrine Biosciences Fundamentals Growth
Neurocrine Stock prices reflect investors' perceptions of the future prospects and financial health of Neurocrine Biosciences, and Neurocrine Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurocrine Stock performance.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0701 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 58.19 B | |||
| Shares Outstanding | 1.93 B | |||
| Price To Book | 7.33 X | |||
| Price To Sales | 44.39 X | |||
| Revenue | 1.13 B | |||
| EBITDA | 138.1 M | |||
| Total Debt | 335.1 M | |||
| Book Value Per Share | 0.88 X | |||
| Cash Flow From Operations | 256.5 M | |||
| Earnings Per Share | 0.41 X | |||
| Total Asset | 2.07 B | |||
About Neurocrine Biosciences Performance
By analyzing Neurocrine Biosciences' fundamental ratios, stakeholders can gain valuable insights into Neurocrine Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurocrine Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurocrine Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Neurocrine Biosciences performance evaluation
Checking the ongoing alerts about Neurocrine Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurocrine Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurocrine Biosciences generated a negative expected return over the last 90 days |
- Analyzing Neurocrine Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurocrine Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Neurocrine Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurocrine Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurocrine Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurocrine Biosciences' stock. These opinions can provide insight into Neurocrine Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |